Cross-reactive cellular, but not humoral, immunity is detected between OC43 and SARS-CoV-2 NPs in people not infected with SARS-CoV-2: Possible role of cT


Journal

Journal of leukocyte biology
ISSN: 1938-3673
Titre abrégé: J Leukoc Biol
Pays: England
ID NLM: 8405628

Informations de publication

Date de publication:
08 2022
Historique:
revised: 07 03 2022
received: 02 07 2021
pubmed: 7 4 2022
medline: 27 7 2022
entrez: 6 4 2022
Statut: ppublish

Résumé

Multiple questions about SARS-CoV-2 humoral and cellular immunity remain unanswered. One key question is whether preexisting memory T or B cells, specific for related coronaviruses in SARS-CoV-2-unexposed individuals, can recognize and suppress COVID-19, but this issue remains unclear. Here, we demonstrate that antibody responses to SARS-CoV-2 antigens are restricted to serum samples from COVID-19 convalescent individuals. In contrast, cross-reactive T cell proliferation and IFN-γ production responses were detected in PBMCs of around 30% of donor samples collected prepandemic, although we found that these prepandemic T cell responses only elicited weak cT

Identifiants

pubmed: 35384035
doi: 10.1002/JLB.4COVCRA0721-356RRR
pmc: PMC9088540
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

339-346

Informations de copyright

© 2022 The Authors. Journal of Leukocyte Biology published by Wiley Periodicals LLC on behalf of Society for Leukocyte Biology.

Références

Front Immunol. 2020 Oct 16;11:586984
pubmed: 33178220
Immunity. 2014 Oct 16;41(4):529-42
pubmed: 25367570
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
J Immunol. 2020 Dec 1;205(11):3130-3140
pubmed: 33148714
Nat Med. 2020 Nov;26(11):1691-1693
pubmed: 32929268
J Virol. 2021 Jan 7;:
pubmed: 33414159
Nat Med. 2021 Jan;27(1):78-85
pubmed: 33184509
J Leukoc Biol. 2022 Aug;112(2):339-346
pubmed: 35384035
Int J Biol Sci. 2020 Mar 15;16(10):1678-1685
pubmed: 32226285
mBio. 2020 Sep 25;11(5):
pubmed: 32978311
Cell. 2022 Feb 17;185(4):603-613.e15
pubmed: 35026152
J Infect. 2020 Dec;81(6):923-930
pubmed: 33127456
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
J Infect Dis. 2021 Feb 13;223(3):409-415
pubmed: 32692346
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 32997649
Clin Infect Dis. 2021 Nov 2;73(9):e3095-e3097
pubmed: 32927483
Lancet Microbe. 2020 Jul;1(3):e111-e118
pubmed: 33230504
Cell. 2020 Nov 25;183(5):1340-1353.e16
pubmed: 33096020
Elife. 2020 Sep 07;9:
pubmed: 32894217
Immunity. 2020 Dec 15;53(6):1258-1271.e5
pubmed: 33296686
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Sci Rep. 2016 Jun 21;6:27944
pubmed: 27323685
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734
pubmed: 32376634
PLoS One. 2018 Aug 29;13(8):e0203037
pubmed: 30157242
Eur J Immunol. 2021 Nov;51(11):2633-2640
pubmed: 34358329

Auteurs

Álvaro Fernando García-Jiménez (ÁF)

Department of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain.

Yaiza Cáceres-Martell (Y)

Department of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain.

Daniel Fernández-Soto (D)

Department of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain.

Pedro Martínez Fleta (P)

Immunology Department, Hospital Universitario La Princesa IIS-IP, Madrid, Spain.

José M Casasnovas (JM)

Department of Macromolecular Structures, National Centre for Biotechnology, CNB-CSIC, CNB, Madrid, Spain.

Francisco Sánchez-Madrid (F)

Immunology Department, Hospital Universitario La Princesa IIS-IP, Madrid, Spain.

José Miguel Rodríguez Frade (JMR)

Department of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain.

Mar Valés-Gómez (M)

Department of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain.

Hugh T Reyburn (HT)

Department of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH